Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Aug;7(4):100547.
doi: 10.1016/j.esmoop.2022.100547. Epub 2022 Jul 15.

Minimal residual disease in gastroesophageal adenocarcinoma: the search for the invisible

N Tarazona  1 , F Gimeno-Valiente  2 , A Cervantes  3
Affiliations
Editorial

Minimal residual disease in gastroesophageal adenocarcinoma: the search for the invisible

N Tarazona et al. ESMO Open. 2022 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosure NT declares advisory board or speaker fees from Amgen, Merck Serono, Pfizer and Servier in the last 5 years. AC declares institutional research funding from Genentech, Merck Serono, Bristol Myers Squibb, Merck Sharp & Dohme, Roche, BeiGene, Bayer, Servier, Lilly, Novartis, Takeda, Astellas and FibroGen; and advisory board or speaker fees from Amgen, Merck Serono, Roche, Bayer, Servier and Pierre Fabre in the last 5 years. FGV has declared no conflicts of interest.

Comment on

  • ctDNA as a biomarker of progression in oesophageal adenocarcinoma.
    Bonazzi VF, Aoude LG, Brosda S, Lonie JM, Patel K, Bradford JJ, Koufariotis LT, Wood S, Smithers BM, Waddell N, Barbour AP. Bonazzi VF, et al. ESMO Open. 2022 Jun;7(3):100452. doi: 10.1016/j.esmoop.2022.100452. Epub 2022 Mar 23. ESMO Open. 2022. PMID: 35798469 Free PMC article.

References

    1. Ferlay J., Colombet M., Soerjomataram I., et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021 doi: 10.1002/ijc.33588. - DOI - PubMed
    1. Chapman P.B., Hauschild A., Robert C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–2516. - PMC - PubMed
    1. Catenacci D.V.T., Tebbutt N.C., Davidenko I., et al. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(11):1467–1482. - PMC - PubMed
    1. Van Cutsem E., Bang Y.J., Mansoor W., et al. A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification. Ann Oncol. 2017;28(6):1316–1324. - PubMed
    1. Lordick F., Kang Y.K., Chung H.C., et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14(6):490–499. - PubMed